Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell...

Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA

CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy for r/r multiple myeloma ( Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA )

Managing Hodgkin lymphoma during the COVID-19 outbreak

Dr Anna Sureda - Hospitalet de Llobregat, Barcelona, Spain

Managing Hodgkin lymphoma during the COVID-19 outbreak ( Dr Anna Sureda - Hospitalet de Llobregat, Barcelona, Spain )

Working up metastatic NSCLC

Dr Depak Dabkara - Tata Medical Center, Kolkata, India

Working up metastatic NSCLC ( Dr Depak Dabkara - Tata Medical Center, Kolkata, India )

Where have we got to with cancer treatment?

Prof Alexander Eggermont - Princess Máxima Center for Pediatric Oncology...

Where have we got to with cancer treatment? ( Prof Alexander Eggermont - Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands )

CART-T cell therapy in young patients with relapsed/refractory ALL

Prof Peter Bader - Universitätsklinikum Frankfurt, Frankfurt, Germany

$CART-T cell therapy in young patients with relapsed/refractory ALL ( Prof Peter Bader - Universitätsklinikum Frankfurt, Frankfurt, Germany )$

HSCT: Donor selection for patients with ALL

Prof Sebastian Giebel - The Maria Skłodowska-Curie Institute of Oncology...

HSCT: Donor selection for patients with ALL ( Prof Sebastian Giebel - The Maria Skłodowska-Curie Institute of Oncology, Gliwice, Poland )

Therapy of Ph-positive adult ALL

Prof Oliver Ottmann - Cardiff University, Cardiff, UK

Therapy of Ph-positive adult ALL ( Prof Oliver Ottmann - Cardiff University, Cardiff, UK )

The role of blinatumomab followed by HSCT in paediatric patients with ALL

Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy

The role of blinatumomab followed by HSCT in paediatric patients with ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )

BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL

Prof Hervé Dombret - University Paris Diderot, Paris, France

BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL ( Prof Hervé Dombret - University Paris Diderot, Paris, France )

Long-term outcomes of subjects with EBV driven PTLD following solid organ or...

Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA

Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT treated with tabelecleucel ( Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA )

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT...

Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo ( Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA )

More from ecancer